B+
Bull case
20%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-08-11 · RankAlpha Sentiment Codex
AIRS
AirsculptANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-08-11 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.75
Analysis reference price unavailable
Analysis 2026-08-11 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-11
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+88.7
Score
AI commentary
The packet contains no recent-news feed or usable social-context coverage, and analyst reaction data is unavailable. The latest primary-source update supports a cautious monitoring view: operational stabilization is visible, but the EBITDA-guidance reduction offsets much of the positive volume signal. Confidence is limited by low coverage and the absence of post-print revisions.
RankAlpha Sentiment Codex - 2026-08-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-11eventQ2 results confirm stabilization but reduce profitability outlookMedium impact
Q2 same-center case volume increased 1.0% for the second consecutive quarter, but reported revenue fell 3% to $42.9 million and adjusted EBITDA declined to $4.9 million. Fiscal 2026 revenue guidance was reaffirmed at the low end of $151-$157 million, while adjusted EBITDA guidance was reduced to $12-$14 million [#SEC-8K-2026-08-10].
2026-08-11catalystManagement communication and new-service rollout provide a near-term sentiment testMedium impact
AirSculpt plans to present at Canaccord Genuity's Growth Conference on August 11 and has entered an exclusive AlloClae partnership to broaden its treatment offering and addressable patient population [#PR-EARNINGS-2026-08-03][#SEC-8K-2026-08-10].
2026-12-31catalystH2 execution could support a modest rerating if volume and margins improveHigh impact
Management describes a broader procedure mix, increased brand marketing, and a more disciplined operating platform. The company also reported cash of $18.8 million, gross debt of approximately $44.2 million, and $5.0 million of revolver capacity at June 30, 2026 [#SEC-8K-2026-08-10]. Sustained procedure growth and delivery against the reduced EBITDA outlook are needed for a durable rerating.
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-11 • Updated nightlySource: Internal modelMethodology